Revinty Ellipta is an inhaler for treating asthma and chronic obstructive pulmonary disease (COPD). In asthma, it is used for regular treatment of patients from 12 years of age: - whose symptoms are not controlled with an inhaled corticosteroid and an inhaled short-acting beta-2 agonist; - whose symptoms are adequately controlled with both inhaled corticosteroids and a long-acting beta-2 agonist. In COPD, it is used in adults who have flare-ups of the disease despite regular bronchodilator treatment (treatment to widen the airways). Revinty Ellipta contains the active substances fluticasone furoate and vilanterol. This medicine is the same as Relvar Ellipta, which is already authorised in the EU. The company that makes Relvar Ellipta has agreed that its scientific data can be used for Revinty Ellipta (‘informed consent’).
Therapeutic Indication
### Therapeutic indication **Asthma Indication** Revinty Ellipta is indicated in the regular treatment of asthma in adults and adolescents aged 12 years and older, where use of a combination product (long-acting beta2-agonist and inhaled corticosteroid) is appropriate: - patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short acting beta2-agonists. **COPD Indication** Revinty Ellipta is indicated for the symptomatic treatment of adults with COPD with a FEV1 <70% predicted normal (post-bronchodilator) in patients with an exacerbation history despite bronchodilator therapy.
Therapeutic Area (MeSH)
ATC Code
R03AK10
ATC Item
vilanterol and fluticasone furoate
Pharmacotherapeutic Group
Adrenergics and other drugs for obstructive airway diseases
Active Substance (Summary)
INN / Common Names
EMA Name
Revinty Ellipta
Medicine Name
Revinty Ellipta
Aliases
N/ANo risk management plan link.
